Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data

BACKGROUND: Many biomarkers have been proposed to be predictive of response to anti-programmed cell death protein-1 (PD-1)/anti-programmed death ligand-1 (PD-L1) checkpoint inhibitors (CPI). However, conflicting observations and lack of consensus call for an assessment of their clinical utility in a...

Descripción completa

Detalles Bibliográficos
Autores principales: So, WeiQing Venus, Dejardin, David, Rossmann, Eva, Charo, Jehad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950975/
https://www.ncbi.nlm.nih.gov/pubmed/36822668
http://dx.doi.org/10.1136/jitc-2022-006464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950975/
https://www.ncbi.nlm.nih.gov/pubmed/36822668
http://dx.doi.org/10.1136/jitc-2022-006464

Ejemplares similares